The sickle cell and thalassaemia screening support service provides advice on when antenatal screening results involving a raised level of Hb F, the fetal version of haemoglobin, should be followed up.
Melanie is the Principal Clinical Scientist leading the haemoglobinopathy and rare anaemias team at the National Haemoglobinopathies Reference Laboratory. Following her PhD in Genetics at Cambridge, she began working as a Clinical Scientist in the Oxford Regional Genomics Laboratory in 2004, specialising in haematological inherited disorders from 2014. She forms the core of the Sickle Cell and Thalassaemia Support Service, in combination with colleagues Jenny Eglinton and Michelle Rugless, who have both worked in haemoglobinopathies for over a decade.
Related content and links
The PHE Screening team
Public Health England (PHE) existed to protect and improve the nation’s health and wellbeing, and reduce health inequalities. It closed on 30 September 2021 and this blog is no longer updated.
Find out more about the implications for health screening in our Changes ahead for the national screening system blog article.
If you want to stay in touch with screening evidence and policy news, you can subscribe to the UK National Screening Committee blog.
Comments and moderation
- Changes ahead for the national screening system 30 September 2021
- What we blogged about in August and September 2021 30 September 2021
- New resources to help improve quality of samples taken in NHS newborn blood spot screening 30 September 2021